The promise and hope of GLP-1 receptor agonists
- PMID: 39608382
- DOI: 10.1016/S2213-8587(24)00315-2
The promise and hope of GLP-1 receptor agonists
Conflict of interest statement
PS reports research grants paid to her institution from the Australian National Health and Medical Research Council, coauthorship of manuscripts with medical writing assistance from Novo Nordisk and Eli Lilly, and a position (unpaid) in the leadership group of the Obesity Collective. JA reports research support from Nestle Healthcare Nutrition, Eli Lilly, Epitomee, the UnitedHealth Group, Novo Nordisk, KVK Tech, Boehringer Ingelheim, Regenron, and Weight Watchers; and serves as a consultant for Amgen, Regeneron, Brightseed, Boehringer Ingelheim, Intuitive, Novo Nordisk, Eli Lilly, and WW.
Comment on
-
Effects of GLP-1 receptor agonists on kidney and cardiovascular disease outcomes: a meta-analysis of randomised controlled trials.Lancet Diabetes Endocrinol. 2025 Jan;13(1):15-28. doi: 10.1016/S2213-8587(24)00271-7. Epub 2024 Nov 25. Lancet Diabetes Endocrinol. 2025. PMID: 39608381
Publication types
LinkOut - more resources
Full Text Sources
